Title :

Patterns of response to crizotinib in recurrent glioblastoma according to alk and met molecular profile in two patients

Author(s) :

Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Chamberlain, Marc C. [Auteur]
Zairi, Fahed [Auteur]
Delmaire, Christine [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Idbaih, Ahmed [Auteur]
Renaud, Florence [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Maurage, Claude-Alain [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172

Gregoire, Valerie [Auteur]

Journal title :

CNS oncology

Abbreviated title :

CNS Oncol

Volume number :

4

Pages :

381-6

Publication date :

2015-01-01

ISSN :

2045-0915

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, ...
Show more >Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
INSERM
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2019-11-27T13:33:33Z
2023-04-21T10:35:55Z